Patient-centered, individualized care is the standard practice goal for patients with type 2 diabetes mellitus (T2DM). To avoid the health risks associated with treatment delay, clinicians need to recognize when intensification of glucose control is appropriate. Accumulating evidence and current treatment guidelines support the notion that glucagon-like peptide-1 (GLP-1) receptor agonists are favorable options to intensify antihyperglycemic therapy. Accordingly, healthcare professionals (HCPs) need to be prepared to address common, modifiable barriers to successful initiation, continuation, and intensification of injectable therapy with GLP-1 receptor agonists while considering the different properties associated with these antihyperglycemic agents in the context of patient clinical characteristics and preferences.
This educational activity is designed to offer practical, evidence-based considerations for appropriately applying the use of GLP-1 receptor agonists for the management of T2DM. Additionally, this online publication features expert discussions designed to provide information that can be immediately applied to clinical practice.